Medicine pack check sheet

Source-linked reading points

• Check the brand, generic name, oral-tablet form, strength per tablet and target market together: the U.S. label uses FARXIGA, PMDA uses フォシーガ in Japan, and historical AstraZeneca China material uses 安达唐®. 5 mg/10 mg identifies the stated strength per tablet; different names, markets or the same dapagliflozin ingredient do not permit independent doubling, halving, substitution or switching.
• Label terms such as diabetes, heart failure or chronic kidney disease cannot be used to infer individual suitability from a package. Changes in kidney function, eating or drinking, acute illness or the perioperative period require the exact prescription and local professional assessment, not self-adjustment from an old label or web summary.
• If diuretics, insulin or other glucose-lowering products are also used, bring the complete medicine list to a pharmacist or prescribing team before any addition, stop, make-up dose or switch. Interaction or hypoglycaemia wording is not a personal “can/cannot use” list.
• Different markets, label updates and repackaging can change package appearance or wording. The name and strength on this page only help locate a source; they cannot authenticate a product in hand or establish current approval status.